Aortech International PLC
20 September 2000
AORTECH INTERNATIONAL plc
Official Opening of AorTech Technology Centre
by Dr. John Reid, Secretary of State for Scotland
AorTech International plc, the Scottish-based manufacturer of
cardiovascular devices, announces the opening of its new facility,
the AorTech Technology Centre, which is adjacent to its existing
premises at the Strathclyde, Business Park, Bellshill.
The new facility will focus on the development of innovative products
and will initially house TruCCOMS, the Continuous Cardiac Output
Monitoring System, and the new tri-leaflet heart valve, which
utilises Elast-Eon, the new bio-stable material.
The facility has allowed AorTech to bring together the various
aspects of the heart valve research, by Glasgow, Leeds and Liverpool
Universities, under one roof together with AorTech's newly expanded
development team.
Eddie McDaid, Managing Director commented:
'The opening of this Technology Centre represents another milestone
in the continued growth and development of AorTech with the focus of
the Group's growth based on its exciting innovative products. The
first of these products, the Continuous Cardiac Output Monitoring
System (TruCCOMS) represents a major improvement in the monitoring of
patients' cardiac output both in operating rooms and in intensive
care.
'The other major innovative product which is in its final stages of
development and testing represents the World's first synthetic tri-
leaflet heart valve, made from the new bio-stable Elast-Eon
materials. This heart valve will revolutionise the replacement of
heart valves throughout the world by introducing a heart valve which
is intended to be as long lasting as mechanical heart valves but with
the added advantage of reduction or elimination of the need for daily
anti-coagulant requirements for patients.
'By securing ownership and rights to these technologies over the last
two years the AorTech group has a strong foundation upon which to
continue to build. We are proud to be at the forefront of medical
technology introducing innovative products which will not only have a
major impact in the global medical device market but will also
enhance and improve people's lives. These new innovative products
will, I am confident, enable AorTech to become a major global medical
device company in the future'.
Enquiries: 20 September 2000
AorTech International plc 01698 746699
Eddie McDaid, Managing Director
College Hill 020 7457 2020
Michael Padley / Nicholas Nelson
Copies of this statement will be available for a period of 14 days
form the Company's registered office:
Phoenix Crescent, Strathclyde Business Park, Bellshill, Scotland ML4 3NU
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.